FDG PET studies in the differential diagnose of atypical parkinsonism and dementia syndromes.
Objective: To describe the fluorodeoxyglucose (FDG) metabolic pattern and clinical features in patients with clinical diagnose of atypical parkinsonism such as Progressive Supranuclear Palsy (PSP),…The Relative Preservation of the Dopaminergic Neuroal Loss of Patients with Parkinson’s Disease Having Dopamine-Unresponsive Resting Tremor
Objective: To investigate the difference of dopaminergic neuronal loss between PD patients with dopamine-unresponsive and -responsive resting tremor. Background: Resting tremor (RT) is one of…18F-labeled FP-CIT PET Findings in a series of cirrhotic patients with parkinsonism
Objective: Our object is to evaluate the cirrhotic patients with parkinsonism using the presynaptic dopamine transporter (DAT) positron emission tomography (PET) imaging for dopaminergic deficit.…Specific Metabolic Brain Networks Associated with Parkinsonian and Cerebellar Variants of Multiple System Atrophy
Objective: To identify specific metabolic brain networks for parkinsonian (MSA-P) and cerebellar (MSA-C) variants of MSA. Background: MSA is associated with a disease-related metabolic brain network (MSARP)…Link between striatal dopamine uptake and cortical dysconnectivity in Parkinson’s disease
Objective: This study aims to explore pathways of reduced striatal dopamine synthesis in PD that may affect striato-cortical connectivity and implicate in altered glucose metabolism…In vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome
Objective: To assess in vivo, with molecular imaging the brain distribution of tau aggregates ([18F]AV1451 PET) and β-amyloid depositions ([18F]AV45 PET) in patients with Corticobasal…Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease
Objective: To directly compare 18F-DOPA with a highly specific dopamine transporter radioligand 11C-PE2I, for the assessment of motor severity and rate of progression in Parkinson's…PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins
Objective: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 ([11C]methylamino pyridin-3-yl buta-1,3-dienyl benzo[d]thiazol-6-ol) in tauopathies, and in conditions not…Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study
Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome
Objective: To evaluate change in AV-1451 positron emission tomography (PET) imaging in patients with Progressive Supranuclear Palsy (PSP) and Cortico-Basal Syndrome (CBS) over 9 months…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 33
- Next Page »